Example: Heart Attack

Search clinical trials for: Modulation of FiO2

Total 10000 results

NCT06404008

Completed

A Controlled Breathing Intervention to Reduce Stress and Improve Symptoms in COPD Patients (REST) (REST)

Stress | COPD | Dyspnea
NCT06725732

Recruiting

Assessment of Nebulized Tranexamic Acid in Functional Endoscopic Sinus Surgery Using Modena Bleeding Score

Blood Loss, Surgical
NCT06653946

Recruiting

the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Ischemic Stroke | Alteplase Adverse Reaction
NCT06286657

Recruiting

Xanthohumol and Viral Infections (XL)

Infection Viral
NCT02303171

Recruiting

Use of Warfarin After the First Trimester in Pregnant Women With APS

Recurrent Miscarriage | Antiphospholipid Syndrome
NCT07065123

Completed

Study on Heart Block Risks Using Outcome-Based Modeling (SAVIOR)

Aortic Stenosis | Left Bundle-Branch Block
NCT05304949

Completed

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity
NCT04347122

Terminated

Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Sarcoma,Soft Tissue | Musculoskeletal Cancer
NCT05886998

Completed

Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury

Acute Lung Injury | Smoke Inhalation Injury
NCT02474810

Completed

Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol

Chronic Renal Insufficiency
NCT05580016

Completed

Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain. (GRADIENT)

Mortality | Abdominal Pain | Emergency Department | Soluble Urokinase Plasminogen Activation Receptor
NCT03723187

Completed

Study of Standard Maintenance Method of Intravenous Port and Post-operation Pain Analysis

Cancer
NCT02947529

Completed

Tranexamic Acid Use in Acute Hip Fractures

Acute Hip Fractures
NCT03606109

Completed

Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid

Tibial Tubercle Osteotomy
NCT02053363

Completed

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

Adult Spinal Deformity
NCT04590794

Completed

SuPAR in Adult Patients With Covid-19 (SPARCOL)

Covid19
NCT01214915

Completed

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

Essential Thrombocythemia (ET)
NCT02863354

Completed

Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy (RECOVERY)

Proliferative Diabetic Retinopathy
NCT02578901

Completed

American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)

Thrombocytopenia
NCT04726007

Unknown

Management of TA in VaS-Patients and HT

VTE After Stroke
NCT02681809

Terminated

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR (CIRCLE)

Disease Progression | Diabetic Retinopathy | Posterior Vitreous Detachment
NCT02026297

Terminated

Tranexamic Acid and Thromboelastography During Cesarean Delivery (TA TEG)

Postpartum Hemorrhage
NCT02607111

Completed

A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients

Kidney Failure
NCT02797704

Terminated

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Corneal Neovascularization
NCT01464723

Completed

Study EvAluating Genotypes While Using Lucentis 2 (SEAGUL2)

Age-Related Macular Degeneration
NCT01476449

Completed

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

Diabetic Retinopathy | Macular Edema
NCT02537054

Completed

Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE) (EyNeP)

Pseudoxanthoma Elasticum
NCT01564108

Completed

The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema

Uveitis Related Cystoid Macular Edema | Steroid-induced Glaucoma - Borderline
NCT02034006

Completed

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (OLIMPIC)

Choroidal Neovascularization Secondary to Pathologic Myopia
NCT02633852

Completed

Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

Diabetic Macular Edema (DME)
NCT00904709

Completed

The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders

Menorrhagia
NCT02329132

Completed

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

Diabetic Macular Edema
NCT00498355

Completed

Lucentis for Inflammatory Macular Edema Trial (LIME)

Uveitis | Cytoid Macular Edema
NCT00831350

Completed

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations (PADDLE)

Retinal Vein Occlusion | Posterior Vitreous Detachment
NCT02095509

Completed

Pharmacokinetics of Enoxaparin in Intensive Care Patients

Venous Thromboembolism
NCT02698566

Completed

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Macular Edema
NCT00769145

Completed

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Corneal Neovascularization
NCT02063035

Completed

Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery

Lumbar Spinal Stenosis | Thoracic Spinal Stenosis
NCT01802684

Completed

OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (VELVET)

Unresectable Metastatic Colorectal Cancer
NCT00358501

Completed

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Severe Hepatic Veno-Occlusive Disease
NCT00657202

Completed

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Neurofibromatosis Type 1 | Cutaneous Neurofibromas
NCT01167764

Withdrawn

Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis

Hemoptysis
NCT00378196

Completed

Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial

Telangiectasia
NCT00363168

Completed

Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

Choroidal Neovascularization
NCT01069341

Completed

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

Proliferative Diabetic Retinopathy | Rubeosis Iridis
NCT00922766

Completed

Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Acute Coronary Syndrome
NCT00567697

Completed

A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

Central Retinal Vein Occlusion | Macular Edema
NCT00885794

Unknown

Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME) (MORE)

Diabetic Macular Edema
NCT00975962

Completed

New Acute Treatment for Stroke - The Effect of Remote PERconditioning

Acute Stroke
NCT00395551

Completed

Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Choroidal Neovascularization

Search clinical trials for: Modulation of FiO2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations